361 related articles for article (PubMed ID: 31359832)
1. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
2. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ;
N Engl J Med; 2018 Apr; 378(15):1408-1418. PubMed ID: 29420164
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
4. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
5. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Iijima K; Nishimura K; Fujii K; Hatayama T; Aoyama J; Deprince K; Lopez-Gitlitz A; McCarthy S; Larsen JS; Li J; Chi KN
Int J Urol; 2021 Mar; 28(3):280-287. PubMed ID: 33295007
[TBL] [Abstract][Full Text] [Related]
6. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide and its use in the treatment of prostate cancer.
Borno HT; Small EJ
Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
[TBL] [Abstract][Full Text] [Related]
8. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
Hauke R
Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide for the treatment of prostate cancer.
Rathkopf DE; Scher HI
Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
[TBL] [Abstract][Full Text] [Related]
10. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
[TBL] [Abstract][Full Text] [Related]
11. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
12. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
13. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
15. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
16. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
[TBL] [Abstract][Full Text] [Related]
17. Apalutamide and Overall Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Brookman-May SD; Li S; Zhang K; Rooney B; Lopez-Gitlitz A; Small EJ
Eur Urol; 2021 Jan; 79(1):150-158. PubMed ID: 32907777
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Aoyama J; Hatayama T; Ito M; Lefresne F; McCarthy S; Mundle S; He J; Chi KN
Int J Urol; 2022 Jun; 29(6):533-540. PubMed ID: 35293030
[TBL] [Abstract][Full Text] [Related]
20. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
